Quarterly report · Q3
4536.TEDINET S100Q4MU
Period2022-04-01 → 2022-12-31
Filed2023-02-09
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥199.8bn | 2022-04-01 → 2022-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥70.9bn | 2022-10-01 → 2022-12-31d | Cons. | Revenue IFRS |
| Revenue | ¥266.3bn | 2021-04-01 → 2022-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥195.8bn | 2021-04-01 → 2021-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥67.0bn | 2021-10-01 → 2021-12-31d | Cons. | Revenue IFRS |
| Operating income | −¥10.1bn | 2022-04-01 → 2022-12-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥8.9bn | 2022-10-01 → 2022-12-31d | Cons. | Operating profit loss IFRS |
| Operating income | ¥26.4bn | 2021-04-01 → 2021-12-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥7.6bn | 2021-10-01 → 2021-12-31d | Cons. | Operating profit loss IFRS |
| Profit before tax | −¥11.6bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥7.5bn | 2022-10-01 → 2022-12-31d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥35.6bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥25.7bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥7.3bn | 2021-10-01 → 2021-12-31d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | −¥16.1bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥6.0bn | 2022-10-01 → 2022-12-31d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥27.2bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥19.3bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥5.0bn | 2021-10-01 → 2021-12-31d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | −¥16.1bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss IFRS |
| Net income | ¥5.9bn | 2022-10-01 → 2022-12-31d | Cons. | Profit loss IFRS |
| Net income | ¥19.3bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss IFRS |
| Net income | ¥5.0bn | 2021-10-01 → 2021-12-31d | Cons. | Profit loss IFRS |
| Total assets | ¥420.1bn | at 2022-12-31 | Cons. | Assets IFRS |
| Total assets | ¥460.0bn | at 2022-03-31 | Cons. | Assets IFRS |
| Total assets | ¥429.6bn | at 2021-12-31 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥119.9bn | at 2022-12-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥123.1bn | at 2022-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥300.3bn | at 2022-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥336.8bn | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥320.8bn | at 2021-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥309.6bn | at 2021-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥300.9bn | at 2022-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥337.5bn | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥321.4bn | at 2021-12-31 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥61.2bn | at 2022-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥83.0bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥67.8bn | at 2021-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥62.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥28.5bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥46.0bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥31.2bn | 2021-04-01 → 2021-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥23.6bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥35.2bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥23.2bn | 2021-04-01 → 2021-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥28.0bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥5.6bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥4.1bn | 2021-04-01 → 2021-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥-41.13 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥15.49 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥68.07 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥48.39 | 2021-04-01 → 2021-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥12.6 | 2021-10-01 → 2021-12-31d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥-41.13 | 2022-04-01 → 2022-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥15.46 | 2022-10-01 → 2022-12-31d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥67.97 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥48.32 | 2021-04-01 → 2021-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥12.59 | 2021-10-01 → 2021-12-31d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 71.6% | at 2022-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 73.4% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 74.8% | at 2021-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
All source rows · 626
| Item | Context | Value | Unit |
|---|---|---|---|
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 45360 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)参天製薬株式会社 | |
| Filer name in english | FilingDateInstant | SANTEN PHARMACEUTICAL CO., LTD. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | IFRS | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2022-04-01 | |
| Current period end date | FilingDateInstant | 2022-12-31 | |
| Type of current period | FilingDateInstant | Q3 | |
| Current fiscal year end date | FilingDateInstant | 2023-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2021-04-01 | |
| Comparative period end date | FilingDateInstant | 2021-12-31 | |
| Previous fiscal year end date | FilingDateInstant | 2022-03-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所プライム市場 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)完全議決権株式であり、権利内容に何ら限定のない当社における標準となる株式。単元株式数は100株です。 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Voting rights (text) | FilingDateInstant | Text · Plus | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithFullVotingRightsTreasurySharesEtcMember | Original text (Japanese)権利内容に何ら限定のない当社における標準となる株式。単元株式数は100株です。 | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithFullVotingRightsOtherMember | Original text (Japanese)同上 | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesLessThanOneUnitMember | Original text (Japanese)権利内容に何ら限定のない当社における標準となる株式。 | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)参天製薬株式会社 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |